BC Week In Review | Feb 17, 2014
Company News

DanDrit Biotech USA, Oxford BioMedica, myTomorrows cancer news

Online patient platform myTomorrows will offer patients access to DanDrit's MelCancerVac and to an undisclosed therapeutic cancer vaccine from Oxford BioMedica. MelCancerVac is a dendritic cell-based vaccine that has completed Phase II testing to treat...
BioCentury | Apr 29, 2013
Strategy

Zerhouni's progress report

When Elias Zerhouni joined Sanofi as the head of R&D in January 2011, the former NIH director decided the pharma's pipeline needed to be pruned and refocused around disease pathways. Two years into the job,...
BC Week In Review | Mar 11, 2013
Clinical News

TroVax: Phase II started

Oxford BioMedica said the Velindre Cancer Centre began the open-label, U.K. Phase II SKOPOS trial to evaluate TroVax every 3 weeks for 9 cycles plus pemetrexed and cisplatin in 26 patients. The trial is funded...
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
BC Week In Review | Oct 15, 2012
Clinical News

TroVax: Phase II discontinued

Oxford stopped an open-label, U.S. Phase II trial comparing TroVax plus docetaxel vs. docetaxel alone in patients with metastatic HRPC due to slower-than-expected patient recruitment. Oxford attributed the slow enrollment to changes in the U.S....
BioCentury | Oct 15, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Celgene Corp. (NASDAQ:CELG) was up $0.70 to $78.42 on Friday after FDA approved an sNDA for Abraxane nab-paclitaxel for first-line treatment of advanced non-small cell lung cancer (NSCLC). The product was first approved...
BC Extra | Oct 11, 2012
Company News

Oxford discontinues U.S. TroVax prostate cancer trial

Oxford BioMedica plc (LSE:OXB) stopped a U.S. Phase II trial of TroVax in patients with metastatic hormone-refractory prostate cancer (HRPC) due to slower-than-expected patient recruitment. Oxford attributed the slow enrollment to changes in the prostate...
BC Week In Review | Jul 16, 2012
Clinical News

TroVax: Phase II started

Oxford BioMedica said researchers at Cardiff University (Cardiff, U.K.) began the open-label, U.K. Phase II TaCTiCC trial to evaluate TroVax with or without cyclophosphamide in up to 54 patients. The trial has funding from Cardiff...
BC Innovations | May 19, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Oncofetal antigen 5T4 (TPBG; 5T4) Patient sample and mouse studies suggest killing 5T4-positive cells could help...
BC Week In Review | Aug 2, 2010
Clinical News

TroVax: Phase II start

This quarter, Oxford BioMedica will begin an open-label, U.S. Phase II trial to evaluate Taxotere docetaxel with or without TroVax in 80 patients. Taxotere is marketed by sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France). Oxford BioMedica...
Items per page:
1 - 10 of 102